AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Revolution Medicines Inc (NASDAQ:RVMD)
155.99 USD
+4.680 3.093%Sponsored Reports
Loading...
| Previous Close (in USD) | 151.31 |
|---|---|
| Change | +4.680 3.093% |
| 52 W H/L (in USD) | 40.630/15.440 |
| EBITDA (in USD) | -522.042M |
| PE Ratio | -- |
| Volume | 1990523 |
| Diluted Eps TTM | -3.84 |
| Total Assets (in USD) | 2088.591M |
|---|---|
| Total Liabilities (in USD) | 262.397M |
| Revenue TTM (in USD) | 4.566M |
| Cash (in USD) | 696.148M |
| Market Cap (in USD) | 6,252.970 M |
| Revenue Per Share TTM | 0.035 |
| Gross Profit TTM (in USD) | -217.693M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Employees: 411
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Mark A. Goldsmith Ph.D. | CEO, Pres & Chairman | 1962 |
| 2. | Mr. Jack Anders | Chief Financial Officer | 1977 |
| 3. | Ms. Margaret A. Horn J.D. | Chief Operating Officer | 1963 |
| 4. | Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Pres of R&D | 1961 |
| 5. | Ms. Xiaolin Wang | Exec. VP of Clinical Devel. | 1971 |
| 6. | Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | NA |
| 7. | Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 1981 |
| 8. | Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | NA |
| 9. | Mr. David L. Pompliano Ph.D. | Founding Chief Scientific Officer | NA |
| 10. | Mr. Walter Reiher Ph.D. | Chief Information Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -249.125M | -187.091M | -108.53M | -52.037M | -41.789M |
| Minority Interest | - | - | - | - | - |
| Net Income | -248.705M | -179.771M | -108.159M | -47.664M | -41.789M |
| Selling General Administrative | 40.586M | 30.45M | 21.428M | 12.406M | 9.41M |
| Gross Profit | 35.38M | 29.39M | 42.983M | 50.041M | 20.165M |
| Reconciled Depreciation | 9.656M | 7.332M | 6.545M | 3.342M | 1.764M |
| Ebit | -258.279M | -188.008M | -110.697M | -54.12M | -41.673M |
| Ebitda | -249.125M | -187.079M | -108.459M | -48.589M | -39.909M |
| Depreciation And Amortization | 9.154M | 0.929M | 2.238M | 5.531M | 1.764M |
| Operating Income | -258.279M | -188.008M | -110.697M | -54.12M | -40.329M |
| Other Operating Expenses | 293.659M | 217.398M | 153.68M | 104.161M | 60.494M |
| Interest Expense | -9.656M | 0.012M | 0.071M | 0.106M | 0.116M |
| Tax Provision | -0.42M | 0M | -0.371M | -4.373M | - |
| Interest Income | 9.154M | 0.929M | 2.238M | 2.189M | 0.777M |
| Net Interest Income | 9.154M | 0.917M | 2.167M | 2.083M | 0.661M |
| Income Tax Expense | -0.42M | -7.32M | -0.371M | -4.373M | -1.344M |
| Total Revenue | 35.38M | 29.39M | 42.983M | 50.041M | 20.165M |
| Total Operating Expenses | 293.659M | 217.398M | 153.68M | 104.161M | 60.494M |
| Cost Of Revenue | - | - | - | - | 50.285M |
| Total Other Income Expense Net | 9.154M | 0.917M | 2.167M | 2.083M | -2.121M |
| Net Income From Continuing Ops | -248.705M | -187.091M | -108.159M | -47.664M | -41.789M |
| Net Income Applicable To Common Shares | -248.705M | -187.091M | -110.378M | -61.902M | -48.82M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 2088.591M | 811.93M | 737.988M | 567.401M | 220.529M |
| Intangible Assets | 57.739M | 58.807M | 59.876M | 60.945M | 62.013M |
| Other Current Assets | 25.072M | 10.569M | 6.79M | 6.988M | 2.486M |
| Total Liab | 262.397M | 126.742M | 135.42M | 92.725M | 67.994M |
| Total Stockholder Equity | 1826.194M | 685.188M | 602.568M | 474.676M | 152.535M |
| Other Current Liab | 74.694M | 29.446M | -20.271M | 10.303M | 14.356M |
| Common Stock | 0.016M | 0.009M | 0.008M | 0.007M | - |
| Capital Stock | 0.016M | 0.009M | 0.008M | 0.007M | 305.109M |
| Retained Earnings | -1137.708M | -701.341M | -452.636M | -265.545M | -157.386M |
| Good Will | 14.608M | 14.608M | 14.608M | 14.608M | 14.608M |
| Other Assets | 0M | 4.594M | 2.495M | 1.389M | 2.78M |
| Cash | 696.148M | 161.412M | 108.497M | 104.268M | 16.659M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 143.851M | 61.984M | 18.931M | 47.176M | 43.052M |
| Current Deferred Revenue | - | 4.459M | 18.931M | 20.592M | 17.124M |
| Net Debt | -608.204M | -97.207M | -41.864M | -71.604M | -16.487M |
| Short Term Debt | 7.369M | 6.773M | 6.214M | 3.672M | 0.172M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 87.944M | 64.205M | 66.633M | 32.664M | 0.172M |
| Other Stockholder Equity | 2963.342M | 1388.3M | 317.584M | 172.697M | 4.738M |
| Property Plant Equipment | - | 73.736M | 71.236M | 8.902M | 7.147M |
| Total Current Assets | 1879.281M | 660.185M | 577.054M | 454.122M | 133.981M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 1156.807M | 483.531M | 468.557M | 336.473M | 106.099M |
| Net Receivables | 1.254M | 4.673M | 5.929M | 6.393M | 8.737M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 0M | - | -12.719M | - | - |
| Accounts Payable | 61.788M | 21.306M | 14.057M | 12.609M | 11.4M |
| Accumulated Other Comprehensive Income | 0.544M | -1.78M | -0.376M | 0.116M | 0.074M |
| Non Currrent Assets Other | 7.032M | 4.594M | 15.214M | 1.389M | 2.78M |
| Non Current Assets Total | 209.31M | 151.745M | 160.934M | 113.279M | 86.548M |
| Capital Lease Obligations | 87.944M | 64.205M | 66.633M | 32.664M | 0.172M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -24.116M | -135.589M | -231.3M | -105.576M | -1.339M |
| Total Cashflows From Investing Activities | -24.116M | -142.117M | -234.233M | -101.969M | -1.339M |
| Total Cash From Financing Activities | 301.432M | 294.179M | 422.776M | 98.658M | 60.847M |
| Net Income | -248.705M | -187.091M | -108.159M | -47.664M | -41.789M |
| Change In Cash | 52.915M | 4.882M | 88.479M | -52.927M | 60.721M |
| Begin Period Cash Flow | 110.234M | 105.352M | 16.873M | 69.8M | 9.079M |
| End Period Cash Flow | 163.149M | 110.234M | 105.352M | 16.873M | 69.8M |
| Total Cash From Operating Activities | -224.401M | -147.18M | -100.064M | -49.616M | 1.213M |
| Depreciation | 9.656M | 7.332M | 6.545M | 3.342M | 1.764M |
| Other Cashflows From Investing Activities | - | - | - | -99.38M | 0.16M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 7.682M | - | - | - |
| Sale Purchase Of Stock | 1.864M | 1.875M | 0.832M | 100.26M | 60.847M |
| Other Cashflows From Financing Activities | 1.523M | 1.063M | 1.877M | -1.37M | 60.427M |
| Capital Expenditures | 10.816M | 6.528M | 2.933M | 2.589M | 1.499M |
| Change In Working Capital | -13.489M | 8.724M | -8.304M | -8.828M | 38.061M |
| Other Non Cash Items | -2.64M | 3.131M | 1.343M | 4.746M | 2.121M |
| Free Cash Flow | -235.217M | -153.708M | -102.997M | -52.205M | -0.286M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Health Care Inv | 2 years ago | 6540577 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 4899118 |
| 3. | BB Biotech AG Ord | 2 years ago | 4646700 |
| 4. | Vanguard Small Cap Index | 2 years ago | 3962036 |
| 5. | iShares Russell 2000 ETF | 2 years ago | 3246531 |
| 6. | Vanguard Small Cap Growth Index Inv | 2 years ago | 2236381 |
| 7. | SPDR® S&P Biotech ETF | 2 years ago | 2207769 |
| 8. | US Small-Cap Growth II Equity Comp | 2 years ago | 2072635 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 1934200 |
| 10. | T. Rowe Price New Horizons | 2 years ago | 1769962 |
| 11. | Vanguard Explorer Inv | 2 years ago | 1693469 |
| 12. | Fidelity Small Cap Index | 2 years ago | 1468483 |
| 13. | T. Rowe Price Health Sciences | 2 years ago | 1450105 |
| 14. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 1332544 |
| 15. | JPMorgan Small Cap Growth A | 2 years ago | 1273828 |
| 16. | iShares Biotechnology ETF | 2 years ago | 1010100 |
| 17. | Janus Henderson Triton D | 2 years ago | 973296 |
| 18. | Janus Henderson US SMID Cap Growth | 2 years ago | 973296 |
| 19. | Fidelity Growth Company Fund | 2 years ago | 966096 |
| 20. | iShares Russell 2000 Growth ETF | 2 years ago | 872426 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Wellington Management Company LLP | 2 years ago | 14882086 |
| 2. | Vanguard Group Inc | 2 years ago | 14757112 |
| 3. | BlackRock Inc | 2 years ago | 12954314 |
| 4. | Baker Bros Advisors LP | 2 years ago | 7549249 |
| 5. | Farallon Capital Management, L.L.C. | 2 years ago | 6736854 |
| 6. | Nextech Invest AG | 2 years ago | 6296740 |
| 7. | State Street Corporation | 2 years ago | 6253361 |
| 8. | Casdin Capital, LLC | 2 years ago | 5714775 |
| 9. | Alphabet Inc | 2 years ago | 5301512 |
| 10. | Bellevue Group AG | 2 years ago | 5073600 |
| 11. | T. Rowe Price Associates, Inc. | 2 years ago | 4814310 |
| 12. | JPMorgan Chase & Co | 2 years ago | 4391629 |
| 13. | Boxer Capital LLC | 2 years ago | 4279464 |
| 14. | FMR Inc | 2 years ago | 4164150 |
| 15. | HHG PLC | 2 years ago | 3912119 |
| 16. | ARCH VENTURE CORP | 2 years ago | 3233490 |
| 17. | Geode Capital Management, LLC | 2 years ago | 2978784 |
| 18. | Woodline Partners LP | 2 years ago | 2960040 |
| 19. | Goldman Sachs Group Inc | 2 years ago | 2106514 |
| 20. | Artal Group S A | 2 years ago | 1695949 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...